Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions
Gastric Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Affliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Contact: Study coordinator (Weiwei Chen)Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Contact: Study coordinator (Yanqiao Zhang)Contact: Study coordinator (Dan Su)Henan Cancer Hospital, Zhengzhou, Henan, China
Contact: Study coordinator (Xiaobing Chen)Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact: Study coordinator (Xianglin Yuan)The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Contact: Study coordinator (Xiaojun Xiang)The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Contact: Study coordinator (Jinghua Sun)Contact: Study coordinator (Lingling Xu)Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jun Zhang)West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Hongfeng Gou)The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Contact: Study coordinator (Xuefen Lei)
Study leads
Ruihua Xu, MD
Principal Investigator
Sun Yat-sen University